Evaluating the effects of Quebec's private-public drug insurance system.
作者信息
Morgan Steven G, Gagnon Marc-André, Charbonneau Mathieu, Vadeboncoeur Alain
机构信息
School of Population and Public Health (Morgan), University of British Columbia, Vancouver, BC; School of Public Policy and Administration (Gagnon), Carleton University, Ottawa, Ont.; Karl Polanyi Institute of Political Economy (Charbonneau), Concordia University; Family and Emergency Medicine Department (Vadeboncoeur), Montreal University, Montréal, Que.
出版信息
CMAJ. 2017 Oct 10;189(40):E1259-E1263. doi: 10.1503/cmaj.170726.
Abstract
摘要
相似文献
1
Evaluating the effects of Quebec's private-public drug insurance system.
CMAJ. 2017 Oct 10;189(40):E1259-E1263. doi: 10.1503/cmaj.170726.
2
Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States.
Milbank Q. 2007 Sep;85(3):469-98. doi: 10.1111/j.1468-0009.2007.00496.x.
3
Bonanza for drug companies. Quebec's public drug plan pays for biotechnology boom.
Can Fam Physician. 2002 Apr;48:831, 833, 836-8.
4
Quebec's proposed wait time guarantees.
CMAJ. 2006 Apr 11;174(8):1075-6. doi: 10.1503/cmaj.060332.
5
Prescription drug benefits for seniors and public/private collaboration.
Beginnings. 2002 May-Jun;22(3):11.
6
Public stewardship of mixed health systems.
Lancet. 2009 Nov 7;374(9701):1577-8. doi: 10.1016/S0140-6736(09)61241-1. Epub 2009 Aug 11.
7
Taking our medicine: who should pay for what?
Healthc Pap. 2004;4(3):27-8; discussion 68-72. doi: 10.12927/hcpap..16873.
8
Lament for a health care system.
CMAJ. 2005 Jul 19;173(2):117, 119. doi: 10.1503/cmaj.050772.
9
The Drug Utilization Review Network of Quebec.
Healthc Manage Forum. 1996 Summer;9(2):44-7. doi: 10.1016/S0840-4704(10)60852-6.
10
Drug coverage insurance as a novel element of private health insurance in Poland.
Acta Pol Pharm. 2013 Jul-Aug;70(4):763-7.
引用本文的文献
1
Characteristics of persons with multiple sclerosis covered by public drug insurance in a Quebec Birth Cohort.
Prev Med Rep. 2025 Apr 30;54:103093. doi: 10.1016/j.pmedr.2025.103093. eCollection 2025 Jun.
2
The impact of prescription drug insurance on cost related non-adherence to medications in Canada: A Heckman sample selection approach.
PLoS One. 2023 Aug 9;18(8):e0289776. doi: 10.1371/journal.pone.0289776. eCollection 2023.
3
Emergency contraception subsidy in Canada: a comparative policy analysis.
BMC Health Serv Res. 2022 Sep 1;22(1):1110. doi: 10.1186/s12913-022-08416-1.
4
Pharmaceutical policies: effects of regulating drug insurance schemes.
Cochrane Database Syst Rev. 2022 May 3;5(5):CD011703. doi: 10.1002/14651858.CD011703.pub2.
5
Inequity in insurance coverage for prescription drugs in New Brunswick, Canada.
Can J Public Health. 2022 Aug;113(4):504-518. doi: 10.17269/s41997-022-00639-3. Epub 2022 Apr 29.
6
Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
Curr Oncol. 2022 Mar 17;29(3):2064-2072. doi: 10.3390/curroncol29030166.
7
A systematic umbrella review of the association of prescription drug insurance and cost-sharing with drug use, health services use, and health.
BMC Health Serv Res. 2022 Mar 3;22(1):297. doi: 10.1186/s12913-022-07554-w.
8
It's Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada".
Int J Health Policy Manag. 2020 Dec 1;9(12):528-530. doi: 10.15171/ijhpm.2020.03.
9
Election 2019: unprecedented hope for universal pharmacare.
CMAJ. 2019 Oct 15;191(41):E1116-E1117. doi: 10.1503/cmaj.191291.
10
How to pay for national pharmacare.
CMAJ. 2018 Nov 26;190(47):E1384-E1388. doi: 10.1503/cmaj.180897.
本文引用的文献
1
Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage.
CMAJ. 2017 Jun 12;189(23):E794-E799. doi: 10.1503/cmaj.161481.
2
Cost-related nonadherence to prescribed medicines among older Canadians in 2014: a cross-sectional analysis of a telephone survey.
CMAJ Open. 2017 Jan 17;5(1):E40-E44. doi: 10.9778/cmajo.20160126. eCollection 2017 Jan-Mar.
3
Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries.
BMJ Open. 2017 Jan 31;7(1):e014287. doi: 10.1136/bmjopen-2016-014287.
4
Mandatory universal drug plan, access to health care and health: Evidence from Canada.
J Health Econ. 2015 Dec;44:80-96. doi: 10.1016/j.jhealeco.2015.08.004. Epub 2015 Aug 19.
5
Estimated cost of universal public coverage of prescription drugs in Canada.
CMAJ. 2015 Apr 21;187(7):491-497. doi: 10.1503/cmaj.141564. Epub 2015 Mar 16.
6
Canadian pharmacare: looking back, looking forward.
Healthc Policy. 2012 Aug;8(1):14-23.
7
Toward higher-performance health systems: adults' health care experiences in seven countries, 2007.
Health Aff (Millwood). 2007 Nov-Dec;26(6):w717-34. doi: 10.1377/hlthaff.26.6.w717.
8
Public/private partnerships for prescription drug coverage: policy formulation and outcomes in Quebec's universal drug insurance program, with comparisons to the Medicare prescription drug program in the United States.
Milbank Q. 2007 Sep;85(3):469-98. doi: 10.1111/j.1468-0009.2007.00496.x.
9
Impact of a cost sharing drug insurance plan on drug utilization among individuals receiving social assistance.
Health Policy. 2003 May;64(2):163-72. doi: 10.1016/s0168-8510(02)00158-6.
10
Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
JAMA. 2001;285(4):421-9. doi: 10.1001/jama.285.4.421.
Zotero 插件